{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:59:24Z","timestamp":1790873964698,"version":"4.1.0"},"reference-count":97,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"BD"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/17425247.2026.2725755","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:16:25Z","timestamp":1788750985000},"page":"1745-1760","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Addressing the needs for large-volume subcutaneous drug delivery: the case for on-body wearable injectors"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7648-2541","authenticated-orcid":false,"given":"Ronald J.","family":"Pettis","sequence":"first","affiliation":[{"name":"Becton Dickinson, Pharmaceutical Systems","place":["Franklin Lakes, USA"]},{"name":"RJPettis Ventures","place":["Emerald Isle, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0295-0"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2402713"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-022-00361-3"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2023.2249232"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2019.100068"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00626-1"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00744"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00790-2"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S303279"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114156"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12946"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13109"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-023-01318-7"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-015-0288-y"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/MDER.S91019"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0097"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12694"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12672"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2023.2219891"},{"key":"e_1_3_5_21_1","volume-title":"EMPAVELI\u00ae (pegcetacoplan) injection, for subcutaneous use [package insert]","author":"Apellis Pharmaceuticals Inc","year":"2025","unstructured":"Apellis Pharmaceuticals Inc. EMPAVELI\u00ae (pegcetacoplan) injection, for subcutaneous use [package insert]. U.S. Food and Drug Administration; 2025."},{"key":"e_1_3_5_22_1","first-page":"77","volume-title":"NOVEL SOLUTIONS FOR ULTRA-LARGE-VOLUME WEARABLE AND PORTABLE SUBCUTANEOUS INJECTORS","author":"Yeh H-J","year":"2025","unstructured":"Yeh H-J, Lai J-R, Cheng T-C. NOVEL SOLUTIONS FOR ULTRA-LARGE-VOLUME WEARABLE AND PORTABLE SUBCUTANEOUS INJECTORS. ONdrugDelivery: MicroMED Co Ltd; 2025. p. 77\u201383."},{"key":"e_1_3_5_23_1","unstructured":"LTS Lohmann Therapie-Systeme AG. On Body Delivery Systems. [cited 2025 Dec 8]. Available from:https:\/\/www.ltslohmann.com\/en\/our-technologies\/obds-on-body-delivery-systems\/#:~:text=Connectivity%20function%20to%20deliver%20product or%20reducing%20time%20in%20clinic"},{"key":"e_1_3_5_24_1","volume-title":"Freedom60\u00ae infusion system instructions for use [F60_Domestic_IFU_337126 Rev D]","author":"KORU Medical Systems","year":"2024","unstructured":"KORU Medical Systems. Freedom60\u00ae infusion system instructions for use [F60_Domestic_IFU_337126 Rev D]. 2024."},{"key":"e_1_3_5_25_1","volume-title":"User manual SCIg60\u00ae infusion system USA users [instructions for use, AS-0010021_2.0]","author":"EMED Technologies Corporation","year":"2025","unstructured":"EMED Technologies Corporation. User manual SCIg60\u00ae infusion system USA users [instructions for use, AS-0010021_2.0]. 2025."},{"key":"e_1_3_5_26_1","volume-title":"Subcutaneous drug delivery: adapting to high-viscosity, large-volume demands","author":"Fontanellaz T","year":"2024","unstructured":"Fontanellaz T, Jost R, Schneider A. Subcutaneous drug delivery: adapting to high-viscosity, large-volume demands. ONdrugDelivery: Ypsomed AG; 2024."},{"key":"e_1_3_5_27_1","unstructured":"Kal\u00e9o. Aerio\u2122 auto-injector platform. [cited 2026 Apr 1]. Available from: https:\/\/kaleo.com\/aerio\/"},{"key":"e_1_3_5_28_1","unstructured":"Becton Dickinson. BD LibertasTM wearable injector [brochure]. 2022. Available from: https:\/\/www.bd.com\/content\/dam\/bd-assets\/na\/pharmaceutical-systems\/documents\/brochure\/bd-libertas-brochure-one-pager.pdf"},{"key":"e_1_3_5_29_1","unstructured":"Enable Injections. enFuse wearable platform. [cited 2025 Dec 3]. Available from: https:\/\/enableinjections.com\/technology\/"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.70962\/CIS2025abstract.227"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.06.002"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0327-9"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2020.1704730"},{"key":"e_1_3_5_34_1","unstructured":"Ypsomed AG. YpsoMate\u00ae 5.5 [brochure 10309598-MSTR-en\/V05]. 2025. Available from: https:\/\/www.ypsomed.com\/files\/media\/03_Documents\/061_YpsoMate%205.5\/YM_BRO_5.5_MSTR-en.pdf"},{"key":"e_1_3_5_35_1","volume-title":"SKYRIZI\u00ae (risankizumab-rzaa) injection, for subcutaneous or intravenous use [Package insert]","author":"AbbVie Inc","year":"2025","unstructured":"AbbVie Inc. SKYRIZI\u00ae (risankizumab-rzaa) injection, for subcutaneous or intravenous use [Package insert]. U.S. Food and Drug Administration; 2025."},{"key":"e_1_3_5_36_1","unstructured":"scPharmaceuticals Inc. FUROSCIX\u00ae (furosemide injection) for subcutaneous use [package insert] U.S. Food Drug Adm. 2025."},{"key":"e_1_3_5_37_1","volume-title":"FreedomEdge\u00ae syringe infusion system instructions for use [347201_RevA]","author":"KORU Medical Systems","year":"2022","unstructured":"KORU Medical Systems. FreedomEdge\u00ae syringe infusion system instructions for use [347201_RevA]. 2022."},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2205540"},{"key":"e_1_3_5_39_1","volume-title":"OCREVUS ZUNOVOTM (ocrelizumab and hyaluronidase-ocsq) injection, for subcutaneous use [package insert]","author":"Genentech Inc","year":"2024","unstructured":"Genentech Inc. OCREVUS ZUNOVOTM (ocrelizumab and hyaluronidase-ocsq) injection, for subcutaneous use [package insert]. U.S. Food and Drug Administration; 2024."},{"key":"e_1_3_5_40_1","volume-title":"HyQvia Dosing & Administration Guide","author":"Takeda Pharmaceuticals","year":"2025","unstructured":"Takeda Pharmaceuticals. HyQvia Dosing & Administration Guide. Takeda Pharmaceuticals; 2025."},{"key":"e_1_3_5_41_1","volume-title":"DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj)injection, for subcutaneous use [package insert]","author":"Janssen Biotech Inc","year":"2025","unstructured":"Janssen Biotech Inc. DARZALEX FASPRO\u00ae (daratumumab and hyaluronidase-fihj)injection, for subcutaneous use [package insert]. U.S. Food and Drug Administration; 2025."},{"key":"e_1_3_5_42_1","volume-title":"RITUXAN HYCELA\u00ae (rituximab and hyaluronidase human) injection, for subcutaneous use [package insert]","author":"Genetech Inc","year":"2021","unstructured":"Genetech Inc. RITUXAN HYCELA\u00ae (rituximab and hyaluronidase human) injection, for subcutaneous use [package insert]. U.S. Food and Drug Administration; 2021."},{"key":"e_1_3_5_43_1","volume-title":"PHESGO\u00ae (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use [package insert]","author":"Genentech Inc","year":"2024","unstructured":"Genentech Inc. PHESGO\u00ae (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection, for subcutaneous use [package insert]. U.S. Food and Drug Administration; 2024."},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-017-0276-2"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712590903530633"},{"key":"e_1_3_5_46_1","unstructured":"S.P.A. C. CRONO S-PID PORTABLE PUMPS for the treatment of primary immunodeficiencies. 2025. Available from: https:\/\/www.canespa.it\/en\/infusion-pump-therapy-with-subcutaneous-immunoglobulins.html"},{"key":"e_1_3_5_47_1","unstructured":"S.P.A. C. CRONO PAR PORTABLE PUMPS for the treatment of parkinson\u2019s disease. 2025. Available from: https:\/\/www.canespa.it\/en\/infusion-pump-parkinson.html"},{"key":"e_1_3_5_48_1","unstructured":"Technologies GA. Product sheet: gx InPulsTM infusor (edition 20052026). 2026. Available from: https:\/\/www.gerresheimer.com\/fileadmin\/user_upload\/user_upload\/gerresheimer\/customer\/product_solutions\/pharma\/proprietary-devices\/on-body-devices\/gx_inpuls_flex\/Product_Sheet_GxInPuls_Flex_2026.pdf"},{"key":"e_1_3_5_49_1","unstructured":"National health services Royal Cornwall hospitals. Apomorphine for treatment of parkinson\u2019s disease shared care guideline v5.1. 2026."},{"key":"e_1_3_5_50_1","volume-title":"HIZENTRA, Immune Globulin Subcutaneous (Human), 20% Liquid [package insert]","author":"CSL Behring","year":"2021","unstructured":"CSL Behring. HIZENTRA, Immune Globulin Subcutaneous (Human), 20% Liquid [package insert]. U.S. Food and Drug Administration; 2021."},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S515565"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44174-025-00479-y"},{"key":"e_1_3_5_53_1","volume-title":"NEULASTA\u00ae (pegfilgrastim) injection, for subcutaneous use [package insert]","author":"Amgen Inc","year":"2025","unstructured":"Amgen Inc. NEULASTA\u00ae (pegfilgrastim) injection, for subcutaneous use [package insert]. U.S. Food and Drug Administration; 2025."},{"issue":"151","key":"e_1_3_5_54_1","first-page":"52","article-title":"Extending patient-friendly drug delivery to high-volume wearable devices","author":"Schnitzler I","year":"2023","unstructured":"Schnitzler I. Extending patient-friendly drug delivery to high-volume wearable devices. Drug Delivery. 2023;(151):52\u201356.","journal-title":"Drug Delivery"},{"key":"e_1_3_5_55_1","unstructured":"SmartDose\u00ae 3.5 on-body delivery system: west pharmaceutical services. Available from: https:\/\/www.westpharma.com\/products\/self-injection-platforms\/smartdose\/smartdose-3-5-wearable-injector-device"},{"key":"e_1_3_5_56_1","unstructured":"SmartDose\u00ae 10 on-body delivery system: west pharmaceutical services. Available from: https:\/\/www.westpharma.com\/products\/self-injection-platforms\/smartdose\/10-large-volume-wearable-injector-device"},{"key":"e_1_3_5_57_1","unstructured":"Elcam Drug Delivery Devices. Elcam drug delivery devices product Catalog. 2025 [cited 2025 Dec 15]. Available from: https:\/\/www.elcam3d.com\/wp-content\/uploads\/2025\/09\/E3D-Elcam-Drug-Delivery-Devices-Interactive-Catalog-2025.pdf"},{"key":"e_1_3_5_58_1","unstructured":"Elcam Drug Delivery Devices. Patch Pump (eLVD) Datasheet. 2024 [cited 2025 Dec 4]. Available from: https:\/\/www.elcam3d.com\/wp-content\/uploads\/2024\/10\/eLVD-13.05.pdf"},{"key":"e_1_3_5_59_1","first-page":"48","volume-title":"SYMBIOZE\u00ae \u2013THE ELECTROMECHANICAL ON-BODY DRUG DELIVERY SYSTEM FOR LARGE-VOLUME IMMUNOTHERAPIES","author":"Malica C","year":"2025","unstructured":"Malica C, Gross C. SYMBIOZE\u00ae \u2013THE ELECTROMECHANICAL ON-BODY DRUG DELIVERY SYSTEM FOR LARGE-VOLUME IMMUNOTHERAPIES. ONdrugDelivery: Nemera; 2025. p. 48\u201352."},{"key":"e_1_3_5_60_1","unstructured":"Stevanato Group. Vertiva\u00aeA pre-filled and pre-loaded on-body delivery system platform suitable for a wide range of therapies. 2025 [cited 2026 Apr 16]. Available from: https:\/\/www.stevanatogroup.com\/en\/products-capabilities\/drug-delivery-systems\/vertiva\/?utm_source=google&utm_medium=cpc&utm_campaign=%5BNAM%5D+%5BPerformance%5D+Brand+Product+%7C+Search&utm_source=google&utm_medium=cpc&utm_term=vertiva%20stevanato&utm_campaign=%5BNAM%5D+%5BPerformance%5D+Brand+Product+%7C+Search&hsa_grp=178189061500&hsa_mt=e&hsa_ver=3&hsa_net=adwords&hsa_ad=743279523321&hsa_acc=3346249540&hsa_kw=vertiva%20stevanato&hsa_tgt=kwd-2476381534237&hsa_src=g&hsa_cam=22401992101&gad_source=1&gad_campaignid=22401992101&gbraid=0AAAAADfAxzQJ64ZI3hkmrfX4Ip9vDpzY3&gclid=EAIaIQobChMIrIuo0dfjkQMV0UtHAR2QCTHuEAAYASAAEgJ_I_D_BwE"},{"key":"e_1_3_5_61_1","unstructured":"Russo RS. inventorUnited states patent application publication: uS 2022\/0143303. United States: 2022."},{"key":"e_1_3_5_62_1","unstructured":"Ypsomed AG. The pre-filled and ready-to-use patch injector. 2026. Available from: https:\/\/www.ypsomed.com\/files\/media\/03_Documents\/08_YpsoDose\/YD_BRO_MSTR-en.pdf"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.06.021"},{"key":"e_1_3_5_64_1","volume-title":"HERCEPTIN HYLECTA\u00ae (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use [package insert]","author":"Genentech Inc","year":"2024","unstructured":"Genentech Inc. HERCEPTIN HYLECTA\u00ae (trastuzumab and hyaluronidase-oysk) injection, for subcutaneous use [package insert]. U.S Food and Drug Administration; 2024."},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.03.017"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23256"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1021\/nn204166z"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.183"},{"key":"e_1_3_5_69_1","volume-title":"UDENYCA\u00ae (pegfilgrastim-cbqv) injection, for subcutaneous use [package insert]","author":"Coherus BioSciences Inc","year":"2023","unstructured":"Coherus BioSciences Inc. UDENYCA\u00ae (pegfilgrastim-cbqv) injection, for subcutaneous use [package insert]. U.S. Food and Drug Administration; 2023."},{"key":"e_1_3_5_70_1","unstructured":"SQ Innovation Inc. Lasix\u00ae ONYU (furosemide injection) for subcutaneous use [package insert]. US Food Drug Adm. 2025."},{"key":"e_1_3_5_71_1","unstructured":"Enable injections enters into strategic partnership with sanofi [internet]. PR newswire. 2019. Available from: https:\/\/www.prnewswire.com\/news-releases\/enable-injections-enters-into-strategic-partnership-with-sanofi-300859890.html"},{"key":"e_1_3_5_72_1","unstructured":"BD evolve\u2122 on-body injector: Becton Dickinson and Company. 2026. Available from: https:\/\/www.bd.com\/en-us\/products-and-solutions\/products\/product-families\/evolve-on-body-injector#overview"},{"key":"e_1_3_5_73_1","first-page":"26","volume-title":"MEETING THE NEED FOR HIGH-VOLUME DRUG DELIVERY WITH ON-BODY BOLUS INJECTORS","author":"Shaked T","year":"2020","unstructured":"Shaked T. MEETING THE NEED FOR HIGH-VOLUME DRUG DELIVERY WITH ON-BODY BOLUS INJECTORS. ONdrugDelivery: Elcam Drug Delivery Devices; 2020. p. 26\u201328."},{"issue":"164","key":"e_1_3_5_74_1","first-page":"36","article-title":"Importance of user-centric design when developing devices for home use","author":"B\u00fcrdel S","year":"2024","unstructured":"B\u00fcrdel S, Abedian R. Importance of user-centric design when developing devices for home use. ONdrugDelivery: Gerresheimer Adv Technol. 2024;(164):36\u201340.","journal-title":"ONdrugDelivery: Gerresheimer Adv Technol"},{"key":"e_1_3_5_75_1","first-page":"42","volume-title":"Unlocking opportunities in on-body delivery systems through a platform technology approach","author":"Allegro A","year":"2024","unstructured":"Allegro A, Cuccato A. Unlocking opportunities in on-body delivery systems through a platform technology approach. ONdrugDelivery: Stevanato Group; 2024. p. 42\u201345."},{"key":"e_1_3_5_76_1","first-page":"8","volume-title":"DIVERGENT DESIGN PHILOSOPHIES IN THE WEARABLE INJECTOR SEGMENT","author":"Jost R","year":"2025","unstructured":"Jost R, K\u00e4ser D. DIVERGENT DESIGN PHILOSOPHIES IN THE WEARABLE INJECTOR SEGMENT. ONdrugDelivery: Ypsomed Delivery Systems; 2025. p. 8\u201311."},{"key":"e_1_3_5_77_1","unstructured":"Amgen announces launch of new neulasta\u00ae (pegfilgrastim) delivery kit [internet]. PR newswire. 2015; Available from: https:\/\/www.prnewswire.com\/news-releases\/amgen-announces-launch-of-new-neulasta-pegfilgrastim-delivery-kit-300043818.html"},{"key":"e_1_3_5_78_1","unstructured":"Coherus Announces U.S. Launch of UDENYCA ONBODY\u2122 a novel and proprietary stateof-the-art delivery system for pegfilgrastim-cbqv [internet]. PR newswire. 2024; Available from: https:\/\/investors.coherus.com\/news-releases\/news-release-details\/coherus-announces-us-launch-udenyca-onbodytm-novel-and"},{"key":"e_1_3_5_79_1","volume-title":"REPATHA (evolocumab) injection, for subcutaneous use [package insert]","author":"Amgen Inc","year":"2021","unstructured":"Amgen Inc. REPATHA (evolocumab) injection, for subcutaneous use [package insert]. U.S. Food and Drug Administration; 2021."},{"key":"e_1_3_5_80_1","unstructured":"Amgen. Repatha\u00ae Pushtronex\u00ae system (on-body-infusor with prefilled cartridge) discontinuation: FREQUENTLY ASKED QUESTIONS (FAQ) [USA-CCF-81893]. Available from: https:\/\/www.repatha.com\/~\/media\/12A733ED009842C68F1DA5F83532C636.ashx"},{"key":"e_1_3_5_81_1","unstructured":"FDA approves first and only single monthly injection for a PCSK9 inhibitor [internet]. PR newswire. 2016. Available from: https:\/\/www.prnewswire.com\/news-releases\/fda-approves-first-and-only-single-monthly-injection-for-a-pcsk9-inhibitor-300296280.html"},{"key":"e_1_3_5_82_1","volume-title":"ULTOMIRIS\u00ae (ravulizumab-cwvz) injection, for intravenous or subcutaneous use [package insert]","author":"Alexion Pharmaceuticals Inc","year":"2022","unstructured":"Alexion Pharmaceuticals Inc. ULTOMIRIS\u00ae (ravulizumab-cwvz) injection, for intravenous or subcutaneous use [package insert]. U.S. Food and Drug Administration; 2022."},{"key":"e_1_3_5_83_1","unstructured":"AstraZeneca. 9M and Q3 2023 results. 2023. Available from: https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2023\/q3\/9M_and_Q3_2023_results_announcement.pdf"},{"key":"e_1_3_5_84_1","unstructured":"scPharmaceuticals Inc. Reports First Quarter 2023 financial results and provides business update [internet]. Biospace. 2023. Available from: https:\/\/www.biospace.com\/scpharmaceuticals-inc-reports-first-quarter-2023-financial-results-and-provides-business-update"},{"key":"e_1_3_5_85_1","unstructured":"SQ Innovation. SQ Innovation\u2019s lasix\u00ae ONYU Now Available for order through major U.S. Pharmaceutical distributors PR newswire. 2026. Available from: https:\/\/www.prnewswire.com\/news-releases\/sq-innovations-lasix-onyu-now-available-for-order-through-major-us-pharmaceutical-distributors-302682200.html#:~:text=%22By%20ensuring%20broad%20availability%20through home%20treatment%20of%20appropriate%20patients.%22"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.10.008"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02477-2"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2506808"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvae083"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvad073"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2484278"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114282"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220980517"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1188\/17.CJON.121-122"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02735-3"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1547108"},{"key":"e_1_3_5_97_1","unstructured":"BD announces first pharma-sponsored clinical trial using BD libertas\u2122 wearable injector technology for biologic drugs [internet]. Becton Dickinson; 2025 Available from: https:\/\/investors.bd.com\/news-events\/press-releases\/detail\/894\/bd-announces-first-pharma-sponsored-clinical-trial-using-bd-libertas-wearable-injector-technology-for-biologic-drugs"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2022.2162037"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2026.2725755","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17425247.2026.2725755","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2026.2725755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:06:37Z","timestamp":1790870797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2026.2725755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":97,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/17425247.2026.2725755"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2026.2725755","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}